mladbrook

[Nature Communications] Researchers report that oxysterol-binding protein-related protein 4 L is expressed in adult T-cell leukemia cells but not normal T-cells.

[Blood] Scientists identified two cell surface proteins expressed on acute myeloid leukemia blasts of many patients that could represent novel targets for immunologic therapies, and confirmed these targets via flow cytometry.

[Journal of Clinical Investigation] The authors found that most of the double knockout mice underwent leukemic transformation at 12-14 months of age. These mice showed myeloblast replacement of a fibrotic bone marrow and widespread leukemic infiltration.

[Therapeutic Advances in Hematology] Researchers summarize the preclinical and clinical rationale for pevonedistat in MDS and AML, review the clinical data of this agent alone and in combination with hypomethylating agents to date, and highlight potential future directions for this agent in myeloid malignancies.

[Mission Bio.] Mission Bio, Inc. announced the initial availability of the industry’s first assay capable of determining measurable residual disease in cancer down to the level of individual cells.

[iScience] Dual inhibition of Enhancer of Zeste Homolog 2 (EZH2) methyltransferase and p38 kinase activities downregulates pEZH2-T367, H3K27me3, and p-p38 pathways in vivo, and reduces triple negative breast cancer growth and metastasis.